Risk factors, diagnosis and treatment of transient hyperinsulinemic hypoglycemia in newborns
10.3760/cma.j.issn.2096-2932.2023.01.006
- VernacularTitle:新生儿暂时性高胰岛素血症性低血糖的危险因素及诊治
- Author:
Dandan ZHAO
1
;
Bo YANG
;
Min LI
;
Leyao WANG
;
Chongxun ZHANG
;
Hongshan SHI
;
Yi REN
;
Di HUANG
;
Zhongyi SUN
;
Xiangyu GAO
Author Information
1. 徐州市中心医院（徐州医科大学徐州临床学院）新生儿科，徐州 221009
- Keywords:
Hyperinsulinemic hypoglycemia;
Risk factors;
Treatment outcome;
Newborn
- From:Chinese Journal of Neonatology
2023;38(1):23-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the risk factors, diagnosis and treatment of transient hyperinsulinemic hypoglycemia (HH) in newborns.Methods:From January 2016 to December 2020, newborns with transient HH (HH group) admitted to our hospital were enrolled in this retrospective nested case-control study. Newborns with similar gestational age (GA) (differences of GA<2 w) without HH were matched with 1∶2 ratio as the non-HH group. Clinical characteristics of the two groups were compared and the risk factors and therapeutic results of HH in newborns were analyzed using SPSS 20.0 statistical software.Results:A total of 39 cases were included in the HH group and 75 cases were matched in the non-HH group. The proportion of small for gestational age (SGA) [51.3%(20/39) vs. 32.0%(24/75)], the amount of amino acids (AA) in intravenous infusion[1.0(0.0,1.0) g/(kg·d) vs. 0.0(0.0,1.0) g/(kg·d)], the incidence of hypoglycemia [(4.3±1.9) times vs. (3.6±1.3) times] and the maximum glucose infusion rate (GIR)[(8.3±2.5) mg/(kg·min) vs. (7.4±1.1) mg/(kg·min)] in the HH group were higher than the non-HH group (all P<0.05). The platelet count in the HH group were lower than the non-HH group [(186.9±60.9)×10 9/L vs. (215.3±61.7)×10 9/L, P<0.05]. SGA ( OR=2.535, 95% CI 1.077~5.971), the amount of intravenous AA ( OR=2.180, 95% CI 1.029~4.619) and the maximum GIR ( OR=1.405, 95% CI 1.088~1.815) were independent risk factors for transient HH. In the HH group, 28/39 cases were treated with Diazoxide or Octreotide and the therapeutic effects were good with few adverse drug reactions (ADR). 37/39 cases were recovered within 28 d of birth and the other 2 cases were recovered at 2.5 m and 3.5 m, respectively. Conclusions:SGA, the amount of intravenous AA and higher GIR are risk factors for transient HH in newborns. Diazoxide or Octreotide are effective with few ADR in the treatment of transient HH. Most patients will recover from transient HH in 2 w to 3 m.
